

## STI/HIV Quarterly Report

## San Mateo County Health, STI/HIV Program

https://www.smchealth.org/hivstds · STI Clinic: 650.573.2385 · Provider STI Reporting: 650.573.2346 650.573.2919 (fax) Issue No. 69 · Quarter 3: Jul 1 - Sep 30, 2023

Vivian Levy MD, STI Controller · Kismet Baldwin-Santana MD, MPH, Health Officer · Asa Ohsaki, MPH Epidemiologist

<b>Table 1</b> STI Cases Reported Among County of San Mateo Residents by           Quarter (Jul 1 - Sep 30) and Year to Date for 2023 and 2022							
		2023		2022			
		3rd Qtr	YTD	3rd Qtr	YTD		
Chlamydia trachomatis (CT)	Total	627	1,995	703	1,832		
	Male	276	916	320	826		
	Female	347	1,068	380	999		
	Transgender/Other/						
Lymphograpy	Unknown <sup>1</sup>	4	11	3	7		
(LGV)	loma Venereum	0	0	0	1		
Gonorrhea (GC)	Total	222	704	210	639		
	Male	176	555	165	500		
	Female	42	138	42	132		
	Transgender/Other/						
	Unknown <sup>1</sup>	4	11	3	7		
GC Clinical Site <sup>2</sup>	Urine	104	313	106	325		
Sile-	Genitourinary	12	69	16	39		
	Rectal	63	195	54	174		
	Pharyngeal	75	246	67	204		
	Unknown/Missing	3	7	4	11		
	DGI <sup>2</sup>	1	1	0	1		
Syphilis	Total	75	238	90	231		
	Female	16	55	12	36		
Early Syphilis⁴	Total	35	127	71	156		
	Male	29	101	60	131		
	Female	4	21	9	19		
	Transgender/Other/ Unknown	2	5	2	6		
Syphilis by Stage	Primary	6	23	9	21		
	Secondary	10	34	22	45		
	Early Latent	19	70	40	90		
	Late Latent	40	111	19	75		
	Congenital	40 0	0	1	3		
	Neurosyphilis <sup>5</sup>	3	6	1	8		

YTD: Year to Date. <sup>1</sup>Due to data limitations and confidentiality concerns, transgender women, transgender men, and gender diverse persons are combined <sup>2</sup>Clinical sites for gonorrhea are non-exclusive (individual patient may have multiple sites tested). <sup>3</sup>Disseminated Gonococcal Infection. <sup>4</sup>Early Syphilis is defined as primary, secondary, and early latent. <sup>5</sup>Cases not included in the total as neurosyphilis is a sequelae and not a stage; the neurosyphilis cases are captured under other syphilis stages.

- As of the third quarter of 2023, CT increased 11% in men and 7% in women compared to this time last year. GC increased 11% in men and 5% in women compared to last year.
- Total syphilis cases increased by 3% and early syphilis decreased 19% compared to this time last year. 23% (n=55) of syphilis cases have been female this year compared to 16% (n=36) last year.
- Specimens tested for HIV increased 41% compared to last year. To date in 2023 HIV positive prevalence is lower at 0.8% (57/7535) than the first three quarters of 2022 at 1.2% (66/5328).

 Table 2
 HIV testing through the San Mateo County Health


 System by Quarter (Jul 1 - Sep 30) and Year to Date for 2023

and 2022 <sup>1</sup>							
	2023		2022				
	3rd Qtr	YTD	3rd Qtr	YTD			
Total Specimens Tested for							
HIV	2,378	7,535	1,898	5,328			
SMC-STI Clinic	31	127	47	90			
STI/HIV Program Outreach <sup>2</sup>	147	316	67	203			
Other County Clinics <sup>3</sup>	2,200	7,092	1,784	5,035			
Total HIV Antibody Positive	14	57	19	66			
SMC-STI Clinic	0	1	0	3			
STI/HIV Program Outreach <sup>2</sup>	1	2	0	0			
Other County Clinics <sup>3</sup>	13	54	19	63			
Total New HIV Cases	4	14	8	20			

<sup>1</sup>The HIV antibody positives do not reflect the true burden of disease. Some patients may be repeat testers. <sup>2</sup>Testing-on-Demand and STI/HIV Program HIV Rapid Tests. <sup>3</sup>Includes all HIV testing (oral and blood) at San Mateo Medical Center (SMMC), SMMC Satellite Clinics, SMC Public Health (PH) Clinics, and PH Subcontractors. Beginning Aug 2015, a 4th generation HIV screening test was implemented. HIV positive cases may not yet be confirmed by HIV-1/HIV-2 differentiation immunoassay.

## Mpox SMC sexual transmission continues; Jynneos vaccine for at risk recommended

The first case in the non-endemic mpox outbreak was detected in the UK in May 2022. CA has had approximately 6,000 cases since 2022. SMC had 86 mpox cases in 2022 and 8 in 2023 to date.



- Visit CDPH for testing and vaccine information
- The JYNNEOS vaccine is safe and effective, and completion of the 2-dose series provides improved protection compared to 1 dose.



Testing: Identifies infections and allows for public health action and supportive treatment/investigational drug access. Think HIV/STI!

